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intermittent spotting. Pelvic ultrasound noted thickened endometri-
um measuring 2.2 cm. FSH was elevated to 32.3 mIU/mL (post-
menopausal = 23.0–116.3 mIU/mL), indicating of her post-menopausal
status. She underwent a dilatation and curettage (D&C).
Initial pathology was reported as poorly differentiated cancer and
the patient was referred to a gynecologic oncologist. On additional
review, there was suggestion of gestational trophoblastic disease. The
tumor cells formed at least three discernible patterns: (1) large, well-
formed, irregularly outlined syncytial aggregates, (2) smaller clusters,(3) collections of large cells with markedly enlarged hyperchromaticIntroduction
Placental site trophoblastic tumors (PSTTs) are the rarest subtype of
gestational trophoblastic neoplasm (GTN), characterized by intermedi-
ate cytotrophoblasts on histology (Hyman et al., 2013). They typically
occur in reproductive-aged females, arising months to years after a
term gestation, but can be seen after any pregnancy (Hassadia et al.,
2005). While most GTNs are exquisitely susceptible to chemotherapy,
PSTTs are relatively chemoresistance (Schmid et al., 2009). Because
hysterectomy is necessary for appropriate treatment, it is imperative
that PSTTs be diagnosed correctly. We present a case of a patient who
was presumed post-menopausal with no reported pregnancies and
non-classical histological presentation of PSTTs.
Case report
A 53-year old G0P0 presumed post-menopausal woman presented
to her gynecologist with postmenopausal bleeding. She had been on
oral contraceptives for birth control until approximately 12 monthsal of University of Pittsburgh
Halket Street, Pittsburgh, PA
r).
. Open access under CC BY-NC-SA license. often linear, more uniform cells resembling cytotrophoblasts, and
nuclei resembling extravillous (intermediate) trophoblasts (Fig. 1A–B).
Frequent strong expression of multiple trophoblastic markers within
these tumor cells suggested a trophoblastic neoplasm.
Quantitative hCG was elevated to 1517.7 mIU/mL. She underwent
total abdominal hysterectomy, bilateral salpingo-oophorectomy, bilat-
eral pelvic and para-aortic lymphadenectomy and omentectomy. Intra-
operatively, the tumor appeared deeply invasive and necrotic, without
evidence of disease outside the uterus.
Gross examination revealed abundant friable and necrotic tumor
involving 80% of the endometrial cavity, abutting the uterine serosa,
and measuring 5 cm in largest dimension (Fig. 2A–B). Fallopian tubes,
ovaries and lymph nodes were benign.
Microscopic examination revealed extensive tumor necrosis.
The dominant pattern was cytologically bizarre, large, inﬁltrative
single neoplastic cells (Fig. 2C–D). After extensive sampling, no
syncytiotrophoblasts were identiﬁed. On immunohistochemical stain-
ing, human placental lactogen (hPL), a germ cell tumor marker often
positive in PSTTs,was positive. Beta hCG, andplacental alkaline phospha-
tase (PLAP) demonstrated scattered positivity. Tumor cells were positive
for inhibin and negative for p63 and CK5/6. Ki-67 highlighted a few
scattered positive cells. The immunohistochemical proﬁle argued against
choriocarcinoma or epithelioid trophoblastic tumor. However, extensive
tumor necrosis and the dominant pattern of cytologically bizarre, large,
inﬁltrative single neoplastic cells are atypical for PSTTs. Taken together,
the neoplasm was best characterized as an unusual malignant tropho-
blastic tumor of intermediate cell type. The monophasic pattern of the
tumor without syncytiotrophoblasts plus the immunoproﬁle was most
consistent with PSTTs.
The patient underwent a CT scan that was negative for metastatic
disease. Since the disease was conﬁned to the uterus, the patient was
Fig. 1. Endometrial curettage. Histologically, the tumor cells formseveral discernible patterns. Some large,well-formed, irregularly outlined syncytial aggregates (A). Smaller clusters, often
linear, tinier, and more uniform cells resembling cytotrophoblasts; and aggregates of large cells with markedly enlarged hyperchromatic nuclei resembling extravillous (intermediate)
trophoblasts (B).
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(FIGO) stage I disease.
After discussion with the patient, the decision was made not to pur-
sue adjuvant therapy. Monthly serum hCG and hPL have been negative
for 10 months. She remains without evidence of disease.Discussion
Placental site trophoblastic tumors were ﬁrst described in 1981 by
Scully and Young. They were considered to be a potentially malignant
neoplasm arising from intermediate trophoblasts (Scully and Young,
1981). Since this initial description, approximately 300 cases have
been reported in the literature.
PSTT typically presents in reproductive-aged females with irregular
bleeding within two years of a normal term pregnancy. In a review of
seven cases of PSTTs among 4998 cases of GTN, Gillespie described
ﬁve of seven after normal female conception, one after multiple gesta-
tion and one with no recorded antecedent pregnancy (Gillespie et al.,
2000). In a review of the literature, Baergen et al., found antecedent
term pregnancy in 57% of cases, abortion in 17%, and with molar preg-
nancies accounting for 26% of cases (Baergen et al., 2006). Furthermore,
while levels are often lower than in choriocarcinoma, they can be highlyFig. 2. Hysterectomy. Gross examination revealed abundant friable and necrotic tumor abuttin
onstrates extensive tumor necrosis and the dominant pattern of cytologically bizarre, large, inﬁvariable andmaynot correlatewith either burden or outcome (Gillespie
et al., 2000; Nigam et al., 2004).
While PSTT nearly two decades after the preceding pregnancy has
been reported, this magnitude of interval is rare (Nigam et al., 2004).
Post-menopausal PSTT is particularly rare. This diagnosis is difﬁcult to
ascertain, often presenting with amenorrhea, which can be overlooked
in a perimenopausal setting (Nigam et al., 2004). Our patient was a G0
with long duration of OCP use, providing a low clinical suspicion for
GTN.
PSTT derives from extravillous trophoblast. The term “intermediate”
trophoblast is commonly used to represent all types of extravillous tro-
phoblast (Baergen, 2011). PSTT shows high invasion and deep inﬁltra-
tion into the myometrium and can penetrate the uterine wall. PSTT
typically lacks extensive hemorrhage though vascular involvement is
common. Microscopic evaluation resembles trophoblastic inﬁltration
but often appears as masses or sheets of cells with large, atypical nuclei
(Shih, 2007). PSTT generally consists of round, polyhedral, or spindle
cells with few multinucleated cells. The pathology of our patient's
tumor showed the dominant pattern of cytologically bizarre, large, inﬁl-
trative single neoplastic cells, which could not discriminate between
GTD and poorly-differentiated cancer. Notably, histologic morphology
is frequently equivocal for PSTTs, with diagnosis depending upon
immunohistochemical staining (Arato et al., 2000).g the uterine serosa, and measuring 5 cm in largest dimension (A–B). The neoplasm dem-
ltrative single neoplastic cells (C–D).
Table 1
Outcomes for reported stage I cases treated with surgery alone.
# of cases Stage Treatment Disease status Follow-up (years)
Hyman et al. (2013) 1 I TAH/BSOw 1 NED 1.2
Hassadia et al. (2005) 6 I TAH 6 NED .25–11
Schmid et al. (2009) 17 I TAH ± BSO ± LND 16 NED
1 Recurrence
2.3–10.0a
Gillespie et al. (2000) 3 I TAH ± BSO 3 NED 3–10
Baergen et al. (2006) 33 I TAH ± BSO 31 NED
1 AWD
1 DOD
1–13
TAH: total abdominal hysterectomy, BSO: bilateral salpingo-oophorectomy, LND: lymph node dissection, NED: no evidence of disease, AWD: alivewith disease, and DOD: dead of disease.
a Follow-up time for all stages.
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phoblastic lesions using p63, hPL, and Ki-67 stains (Shih, 2007). p63, a
p53-like tumor suppressor, is used in differentiating PSTTs and exagger-
ated placental site (EPS) from other trophoblastic lesions, with positive
staining associated with chorionic-type trophoblastic disease. Human
placental lactogen (hPL), normally expressed by syncytiotrophoblast,
is highly expressed in the trophoblasts of placental site trophoblastic
tumors and EPS but minimally expressed in epithelioid trophoblastic
tumors (ETT) and placental site nodules (PSN). Together, p63 and hPL
can be used to differentiate implantation site trophoblastic disease
from chorionic disease and choriocarcinoma. Ki67 is a marker of prolif-
eration. In separating implantation site trophoblastic diseases, Ki-67
can be used to differentiate EPS from PSTTs. In PSTTs and ETT, 8–20%
of cells will stain positive for Ki-67, whereas in EPS, the intermediate
trophoblasts stain negatively for Ki-67. Lastly, B-hCG is used to identify
choriocarcinoma. In this case, the tumor stained negative for p63 and
positive for hPL with rare B-hCG positivity. These results are consistent
with the trophogram results of implantation site lesions. Ki-67 staining
was scattered positive, which is more consistent with PSTTs than EPS.
Clear diagnosis of PSTTs drastically alters the predicted clinical
course and recommended treatment. While GTNs are generally exqui-
sitely sensitive to chemotherapy, treatment of PSTTs is primarily surgi-
cal, particularly if the disease is conﬁned to the uterus. In a review by
Gillespie et al., patients with disease conﬁned to the uteruswere treated
surgically without chemotherapy and remained disease free with
follow-ups ranging from 3 to 9 years (Gillespie et al., 2000). Similarly,
Hassadia et al., found no recurrences in stage I disease, with six of
eight treated with surgery alone, with 3 months to 10 years of follow-
up (Hassadia et al., 2005). Additionally, Schmid et al. provided evidence
for less recurrence for local disease treated with surgery when com-
pared to treatment with chemotherapy (Schmid et al., 2009). If the
disease is widespread, prognosis is much poorer and chemotherapy
may play a larger role. In the review by Gillespie, the two patients
who died had metastatic disease at diagnosis (Gillespie et al., 2000).
Hassadia's data exhibited a similar pattern: while disease conﬁned to
the uterus was treated surgically with good success, four of nine
patients with metastatic disease died and one continued to have active
disease at follow-up (Hassadia et al., 2005). In a review of 17 patients
with PSTTs, Hyman et al. described nine patients with advanced disease
all receiving cisplatinum-containing therapy. The three surviving
patients had all received EP/EMA. Of the ﬁve stage IV mortalities, an
average of four lines of therapy was used and median survival was
12.6 months (Table 1).Prognostic factors for PSTTs include: mitotic index, time since ante-
cedent pregnancy, serum beta hCG, necrosis, and depth of myometrial
invasion (Baergen et al., 2006). In 2009, FIGO adopted a staging system
that reﬂects extent of the disease coupled with a prognostic score mod-
iﬁed from the World Health Organization criteria. Both interval time
since antecedent pregnancy alone and FIGO stage have been shown to
be strong prognostic factors. Our patient has stage I disease with a
suspected antecedent pregnancy within the last year. Her tumor also
lacked many of the concerning histologic features: vascular invasion,
deep myometrial invasion, serosal involvement or a high-mitotic
index (Schmid et al., 2009). Overall, this patient has a good prognosis
for remaining disease-free after surgical treatment.
Written informed consent was obtained from the patient for publi-
cation of this case report and accompanying images. A copy of the writ-
ten consent is available for review by the Editor-in-Chief of this journal
on request.
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